These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 28201726)

  • 41. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis.
    Matsunaga S; Kishi T; Iwata N
    Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25548104
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Physostigmine for Alzheimer's disease.
    Coelho F; Birks J
    Cochrane Database Syst Rev; 2001; 2001(2):CD001499. PubMed ID: 11405996
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Velnacrine for Alzheimer's disease.
    Birks J; Wilcock GG
    Cochrane Database Syst Rev; 2004; (2):CD004748. PubMed ID: 15106259
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Personalized Prediction of Alzheimer's Disease and Its Treatment Effects by Donepezil: An Individual Participant Data Meta-Analysis of Eight Randomized Controlled Trials.
    Yoshida K; Seo M; Luo Y; Sahker E; Cipriani A; Leucht S; Iwatsubo T; Efthimiou O; Furukawa TA
    J Alzheimers Dis; 2022; 89(4):1143-1157. PubMed ID: 35988219
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Hansen RA; Gartlehner G; Webb AP; Morgan LC; Moore CG; Jonas DE
    Clin Interv Aging; 2008; 3(2):211-25. PubMed ID: 18686744
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rivastigmine for Alzheimer's disease.
    Birks J; Iakovidou V; Tsolaki M
    Cochrane Database Syst Rev; 2000; (2):CD001191. PubMed ID: 10796621
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
    Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Green C; Picot J; Loveman E; Takeda A; Kirby J; Clegg A
    Pharmacoeconomics; 2005; 23(12):1271-82. PubMed ID: 16336020
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.
    Fullerton T; Binneman B; David W; Delnomdedieu M; Kupiec J; Lockwood P; Mancuso J; Miceli J; Bell J
    Alzheimers Res Ther; 2018 Apr; 10(1):38. PubMed ID: 29622037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Donepezil for mild and moderate Alzheimer's disease.
    Birks J S; Melzer D
    Cochrane Database Syst Rev; 2000; (2):CD001190. PubMed ID: 10796620
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.
    Aronson S; Van Baelen B; Kavanagh S; Schwalen S
    Drugs Aging; 2009; 26(3):231-9. PubMed ID: 19358618
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer's disease: a cumulative meta-analysis and trial sequential analysis.
    Blanco-Silvente L; Castells X; Garre-Olmo J; Vilalta-Franch J; Saez M; Barceló MA; Capellà D
    Eur J Clin Pharmacol; 2019 Dec; 75(12):1659-1667. PubMed ID: 31435707
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Utility of an effect size analysis for communicating treatment effectiveness: a case study of cholinesterase inhibitors for Alzheimer's disease.
    Peters KR
    J Am Geriatr Soc; 2013 Jul; 61(7):1170-4. PubMed ID: 23711226
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evidence-based pharmacotherapy of Alzheimer's disease.
    Evans JG; Wilcock G; Birks J
    Int J Neuropsychopharmacol; 2004 Sep; 7(3):351-69. PubMed ID: 15228642
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.